HilleVax, Inc.

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Novartis To Pay Argo $185m Up Fron

Several weeks after it first planned to go public in the US, China-based Adlai Nortye Ltd. launched its initial public offering on 29 September and a concurrent private placement that together gross

Biopharma financings during the second quarter of 2022 reached $12.5bn. The largest was by Blueprint Medicines Corporation (precision therapies for cancer and blood disorders) through an arrangement